Prothix Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private

Prothix General Information

Description

Developer of bio-pharmaceutical products intended to give protein therapeutics for inflammatory and coagulation disorders. The company's bio-pharmaceuticals are monoclonal antibody products which includes humanization and de-immunization of human cells sensitized with anti-human leukocyte antigen antibodies, enabling medical professionals to monitor and treat thromboembolic, inflammatory and coagulation disorder.

Contact Information

Website
www.prothix.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • Utrecht
  • Netherlands
+31 06 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Prothix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-May-2021 00000 Completed Generating Revenue
1. Early Stage VC 15-Aug-2011 00000 00000 Completed Generating Revenue
To view Prothix’s complete valuation and funding history, request access »

Prothix Patents

Prothix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017236063-A1 Monoclonal antibodies against the active site of factor xi and uses thereof Pending 23-Mar-2016 000000000
EP-3433279-A1 Monoclonal antibodies against the active site of factor xi and uses thereof Pending 23-Mar-2016 000000000
JP-2019516395-A Monoclonal antibodies against the active site of factor xi and their use Pending 23-Mar-2016 000000000
US-20190106509-A1 Monoclonal antibodies against the active site of factor xi and uses thereof Granted 23-Mar-2016 000000000
US-11059905-B2 Monoclonal antibodies against the active site of factor xi and uses thereof Active 23-Mar-2016 C07K16/36 0

Prothix Executive Team (3)

Name Title Board Seat Contact Info
Rene Verdonk MD Co-Founder & Chief Executive Officer
Cornelis Hack Ph.D Co-Founder & Chief Scientific Officer
You’re viewing 2 of 3 executive team members. Get the full list »

Prothix Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 0000000 Drug Discovery
To view Prothix’s complete investments history, request access »